KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Accumulated Expenses (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Accumulated Expenses data on record, last reported at $10.7 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 96.91% year-over-year to $10.7 million; the TTM value through Sep 2025 reached $10.7 million, down 96.91%, while the annual FY2024 figure was $91.1 million, 71.07% down from the prior year.
  • Accumulated Expenses reached $10.7 million in Q3 2025 per SRPT's latest filing, down from $55.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $350.4 million in Q2 2024 and bottomed at $1.0 million in Q2 2021.
  • Average Accumulated Expenses over 5 years is $82.3 million, with a median of $29.7 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: crashed 99.34% in 2021, then skyrocketed 13238.56% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $48.3 million in 2021, then plummeted by 82.12% to $8.6 million in 2022, then soared by 3547.49% to $315.0 million in 2023, then tumbled by 71.07% to $91.1 million in 2024, then tumbled by 88.3% to $10.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $10.7 million in Q3 2025, $55.2 million in Q2 2025, and $35.3 million in Q1 2025.